Skip to main content
. 2017 Sep 21;7:12075. doi: 10.1038/s41598-017-12458-5

Figure 3.

Figure 3

Characterization of the AT12-015 mAb resistant (MAR) HPeV3 variant. (a) Nonlinear regression analysis of the neutralizing activity of a human AT12-015 mAb against the HPeV3 A308/99 wild-type (wt) and the MAR HPeV3 variant. Data presented as the mean ± SD. (b) Immunofluorescence imaging of HPeV3 A308/99 wt and MAR variant infected HT29 cells stained by a rabbit HPeV1 antiserum (HPeV1 pAb) or the AT12-015 mAb. (c) Amino acid mutations in the MAR HPeV3 variant as compared to the A308/99 wt and the clinical isolates. Capsid surface-exposed residues are highlighted in red. (d) HPeV3 roadmap of capsid exterior. Capsid proteins VP0 (blue), VP3 (green) and VP1 (pink), the AT12-015 Fab footprint (yellow contour), and also amino acid mutations in variant resistant to AT12-015 are shown (red).